Cargando…

Inhibition of chymotrypsin-like activity of the proteasome by ixazomib prevents mitochondrial dysfunction during myocardial ischemia

The heart is critically dependent on mitochondrial respiration for energy supply. Ischemia decreases oxygen availability, with catastrophic consequences for cellular energy systems. After a few minutes of ischemia, the mitochondrial respiratory chain halts, ATP levels drop and ion gradients across c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sánchez, Gina, Chalmers, Stefanie, Ahumada, Xavier, Montecinos, Luis, Olmedo, Ivonne, Eisner, Veronica, Riveros, Ana, Kogan, Marcelo J., Lavandero, Sergio, Pedrozo, Zully, Donoso, Paulina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250417/ https://www.ncbi.nlm.nih.gov/pubmed/32453773 http://dx.doi.org/10.1371/journal.pone.0233591

Ejemplares similares

Activation of Chymotrypsin-Like Activity of the Proteasome during Ischemia Induces Myocardial Dysfunction and Death
por: Sanchez, Gina, et al.
Publicado: (2016)

Communication Between Cardiomyocytes and Fibroblasts During Cardiac Ischemia/Reperfusion and Remodeling: Roles of TGF-β, CTGF, the Renin Angiotensin Axis, and Non-coding RNA Molecules
por: Flores-Vergara, Raúl, et al.
Publicado: (2021)

Polycystin-1 Is a Crucial Regulator of BIN1 Expression and T-Tubule Remodeling Associated with the Development of Dilated Cardiomyopathy
por: Díaz-Vesga, Magda C., et al.
Publicado: (2022)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

High-Fat-Diet-Induced Obesity Produces Spontaneous Ventricular Arrhythmias and Increases the Activity of Ryanodine Receptors in Mice
por: Sánchez, Gina, et al.
Publicado: (2018)

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2018)

Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment
por: Li, Haoyu, et al.
Publicado: (2016)

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies
por: Smith, David C., et al.
Publicado: (2015)

The Proteasome Inhibitor Ixazomib Inhibits the Formation and Growth of Pulmonary and Abdominal Osteosarcoma Metastases in Mice
por: Harris, Michael A., et al.
Publicado: (2020)

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
por: Gupta, Neeraj, et al.
Publicado: (2016)

Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells
por: Augello, Giuseppa, et al.
Publicado: (2018)

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
por: Manda, Sudhir, et al.
Publicado: (2020)

Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors
por: Perbandt, Markus, et al.
Publicado: (2022)

FORMATION OF NEW CRYSTALLINE ENZYMES FROM CHYMOTRYPSIN : ISOLATION OF BETA AND GAMMA CHYMOTRYPSIN
por: Kunitz, M.
Publicado: (1938)

Nanoparticle-Mediated Angiotensin-(1-9) Drug Delivery for the Treatment of Cardiac Hypertrophy
por: Sepúlveda-Rivas, Sabrina, et al.
Publicado: (2021)

Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma
por: Liu, Wei, et al.
Publicado: (2017)

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
por: Assouline, S E, et al.
Publicado: (2014)

Hemiacetal stabilization in a chymotrypsin inhibitor complex and the reactivity of the hydroxyl group of the catalytic serine residue of chymotrypsin
por: Cleary, Jennifer A., et al.
Publicado: (2014)

Sweet Syndrome Associated with Ixazomib
por: Yavaşoğlu, İrfan, et al.
Publicado: (2021)

Ixazomib-Associated Skin Exfoliation
por: Zhang, Yali, et al.
Publicado: (2022)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
por: Gupta, Neeraj, et al.
Publicado: (2016)

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
por: Gupta, Neeraj, et al.
Publicado: (2017)

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
por: Roeten, Margot S.F., et al.
Publicado: (2021)

Partial and selective inactivation of thrombokinase by chymotrypsin.
por: Milstone, J. H., et al.
Publicado: (1971)

The Role of Trypsin:Chymotrypsin in Tissue Repair
por: Shah, Dilip, et al.
Publicado: (2017)

Detection of Chymotrypsin by Optical and Acoustic Methods
por: Piovarci, Ivan, et al.
Publicado: (2021)

The Association of Ascorbic Acid, Deferoxamine and N-Acetylcysteine Improves Cardiac Fibroblast Viability and Cellular Function Associated with Tissue Repair Damaged by Simulated Ischemia/Reperfusion
por: Parra-Flores, Pablo, et al.
Publicado: (2019)

Endothelial activation impairs the function of small extracellular vesicles
por: Herrera-Zelada, Nicolas, et al.
Publicado: (2023)

Colecistectomía laparoscópica complicaciones
por: Lara Riveros, Zully
Publicado: (1998)

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

AN ENZYME IN MAST CELLS WITH PROPERTIES LIKE CHYMOTRYPSIN
por: Benditt, Earl P., et al.
Publicado: (1959)

Early Experiments in the Quest of an Active Center in Chymotrypsin
por: Balls, A. K.
Publicado: (1962)

Identification of the anticancer effects of a novel proteasome inhibitor, ixazomib, on colorectal cancer using a combined method of microarray and bioinformatics analysis
por: Fan, Qiaowei, et al.
Publicado: (2017)

Herpud1 negatively regulates pathological cardiac hypertrophy by inducing IP3 receptor degradation
por: Torrealba, Natalia, et al.
Publicado: (2017)

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
por: Kumar, Shaji K., et al.
Publicado: (2019)

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling
por: Gupta, Neeraj, et al.
Publicado: (2017)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
por: Haq, M., et al.
Publicado: (2021)

Elevated plasma 20S proteasome chymotrypsin-like activity is correlated with IL-8 levels and associated with an increased risk of death in glial brain tumor patients
por: Koper-Lenkiewicz, Olga Martyna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p7fp4prd8qv1qh8pu0ig7gjo3m